Back to Search
VERED STEARNS, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1861420945IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D59325(MD)326987(NY)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
MD042582(DC)
Education
OTHER
Class of 1992
Research & Publications (20)
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
PMID 16192581·J Clin Oncol·2005
3-trial
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
PMID 15569989·Clin Cancer Res·2004
3-trial
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
PMID 15623610·Clin Cancer Res·2004
3-trial
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
PMID 14652237·J Natl Cancer Inst·2003
3-trial
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
PMID 12538460·Clin Cancer Res·2003
8-other
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.
PMID 11923129·Ann Surg Oncol·2002
8-other
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.
PMID 10690382·Ann Oncol·2000
3-trial
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.
PMID 19332723·J Clin Oncol·2009
8-other
Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
PMID 19398943·Clin Adv Hematol Oncol·2009
6-review
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
PMID 19421167·Pharmacogenomics J·2009
2-rct
Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
PMID 19541862·Clin Chem·2009
7-preclinical
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.
PMID 19564528·J Clin Oncol·2009
4-observational
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.
PMID 19332718·J Clin Oncol·2009
8-other
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
PMID 19153830·Breast Cancer Res Treat·2009
3-trial
Concordance of cancer patients' function, symptoms, and supportive care needs.
PMID 19657724·Qual Life Res·2009
8-other
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
PMID 19200418·J Natl Compr Canc Netw·2009
6-review
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
PMID 19018086·J Clin Oncol·2008
8-other
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
PMID 19019258·Expert Rev Mol Med·2008
6-review
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
PMID 19086600·Oncology (Williston Park)·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1861420945
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile